Humacyte, Inc.

Humacyte, Inc. (Nasdaq: HUMA) is a clinical-stage biotechnology company focused on regenerative medicine, specifically the development of bioengineered human acellular vessels. The company became publicly traded in 2021 following its merger with Alpha Healthcare Acquisition Corp, a SPAC sponsored by Alpha Healthcare Holdings LLC that completed its IPO in 2020. Humacyte operates in the healthcare and life sciences sector, targeting vascular repair and reconstruction applications. The company filed an 8-K current report with the SEC on May 8, 2026, accession number 0001104659-26-057974, continuing its reporting obligations as a public company. Sign up at SpacDesk for full filing history, sponsor data, and real-time SPAC analytics on HUMA and hundreds of other deals.